Lung Adenocarcinoma Brain Metastases Survival Analysis

Rui Wang's retrospective cohort study on figshare analyzes 172 treatment-naïve, driver-negative lung adenocarcinoma patients with synchronous brain metastases. The dataset compares overall survival and intracranial progression-free survival between patients receiving immunochemotherapy with or without brain radiotherapy over a median 36.5-month follow-up.

Use Cases

• Analyze overall survival (OS) differences between the Combination and Systemic therapy groups from the 172-patient cohort.
• Model intracranial progression-free survival (iPFS) using hazard ratios and confidence intervals provided in the study results.
• Compare intracranial objective response rate (iORR) and extracranial objective response rate (eORR) between the two treatment groups.

Strengths

• Directly compares two treatment strategies across 172 matched patients.
• Reports specific median survival times (e.g., 23.5 vs. 17.5 months OS) with hazard ratios and P-values.
• Includes a median follow-up duration of 36.5 months for outcome assessment.

Limitations

• Dataset is a 13.0 KB DOCX file containing summary results, not the underlying patient-level data.
• Sample size of 172 patients limits statistical power for subgroup analyses.
• Retrospective study design may introduce selection bias compared to a randomized trial.

Provenance

Source

figshare, author Rui Wang.

Collection Method

Retrospective cohort study of eligible patients divided into two matched groups.

Time Range

Study period not specified; median follow-up was 36.5 months.

Freshness

Last updated March 2026.

Geography

null